Tag - AERI

Developments

Aerie Pharma to acquire dry eye specialist Avizorex Pharma of Spain

Aerie Pharmaceuticals (NASDAQ:AERI) agreed to acquire Avizorex Pharma, a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. Under the accord, Aerie would make an...

November 18, 2019

Developments

Aerie Pharma receives positive CHMP opinion for Rhokiinsa in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Aerie Pharmaceuticals’ (NASDAQ:AERI) marketing authorization application (MAA) for Rhokiinsa solution. The...

September 20, 2019

Developments

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Aerie Pharmaceuticals (NASDAQ:AERI) priced $275-million principal amount of 1.5% convertible senior notes due 2024. The offering was increased to $275-million from a previously announced size of $250-million. The notes...

September 5, 2019

Developments

FDA clears Aerie Pharma’s Rocklatan in glaucoma or ocular hypertension

The FDA approved Aerie Pharmaceuticals’ (NASDAQ:AERI) Rocklatan ophthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Aerie, which launched Rhopressa in...

March 13, 2019

Tag - AERI

Aerie Pharma to acquire dry eye specialist Avizorex Pharma of Spain

Aerie Pharma receives positive CHMP opinion for Rhokiinsa in EU

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

FDA clears Aerie Pharma’s Rocklatan in glaucoma or ocular hypertension

General

More